Quinolone antibacterials, originally derived from anti-malarial compounds, have been developed through side-chain and nuclear manipulation, notably by piperazine and other monoor bi-cyclic substitutions at the 7 position (giving anti-pseudomonal activity and greater antiGram-negative activity) and fluorination at various sites (giving increased anti-Gram-positive activity). The class has now been in clinical use for 40 years. Increased activity has not been without cost: for example, specific idiosyncratic reactions have consigned agents such as the 1-(2,4)-difluorophenyl compounds, such as temafloxacin (haemolytic uraemic syndrome) and trovafloxacin (hepatotoxic reactions), to restriction, suspension or withdrawal. Class adverse drug reactions (ADRs), variable in frequency and severity within the group, have significantly affected individual groups of compounds, such as the 8-chloro derivatives (Bay y 3118, clinafloxacin and sitafloxacin), which, whilst extremely potent, are also highly phototoxic and have largely been discarded.
Introduction
One proposed grouping of the fluoroquinolones describes the progress of the class from the first to the third generations. An alternative classification is described within this supplement. The development of newer fluoroquinolones and naphthyridones cannot fail to be influenced by the deficiencies of their precursors and, for the highly potent third-generation agents, tolerability and adverse effects will be prime determinants of success or failure. Whilst molecular configurations can be manipulated in the search for safer compounds, surprises still occur, such as the withdrawal of grepafloxacin in 1999 on cardio-toxicological grounds. Not all relationships between structure and adverse drug reaction (ADR) are adequately defined. Thus, whilst earlier agents, such as ciprofloxacin, which now exceeds 340 million prescription episodes, attest to the overall safety of the group, new derivatives may now require post-marketing assessment in several million exposed patients to placate anxieties concerning recently highlighted class and individual ADRs.
The development of quinolones
Originating in the anti-malarial class, modern quinolones have evolved via nuclear and side-chain modification from 1,8-naphthyridine (first generation) molecules to compounds characterized by ever increasing spectra of activity and potency, together with trends to longer elimination half-lives which allow once daily dosing. 1, 2 The individual compounds also have somewhat differing class and specific ADR profiles. These changes, occurring over four decades, can be summarized as follows.
First-generation agents (nalidixic acid) include cinoxacin (cinnoline) and the progenitor fluorinated agent, flumequine, and 7-piperazinyl derivatives, such as pipemidic acid. Several of these compounds, notably pipemidic acid, caused significant CNS problems and small piperazine-like side-chains at the 7-position are recognized to be associated with a higher incidence of CNS ADRs.
Second-generation agents can be subdivided into: 2A agents, typified by ciprofloxacin, which remains the most potent fluoroquinolone against Gram-negative bacterial pathogens, including Pseudomonas aeruginosa; and 2B agents, which have moderately increased anti-Gram-positive potency. Of these, only levofloxacin remains generally available, all others having been withdrawn or discarded due to adverse reactions. These included temafloxacin (haemolytic uraemic syndrome), 3 grepafloxacin (cardiac toxicity) 4 and sparfloxacin (cardiotoxicity and phototoxicity). 5 Third-generation agents, which can be subdivided into 3A and 3B agents. 3A agents are characterized by markedly increased potency against Gram-positive pathogens, notably the pneumococci (MIC range 0.06-0.25 mg/L). Comprised initially of trovafloxacin (suspended due to serious hepatotoxicity 5,7 ) and subsequently the 8-methoxyquinolones, moxifloxacin 1, 2, 8 and gatifloxacin, 5,9,10 which have satisfactory ADR profiles; the most recent addition is garenoxacin 11 [a novel des(6)fluoroquinolone], structurally related to the 8-methoxy subclass, full safety data on which have yet to be published. 3B agents are represented by gemifloxacin, 2 the most potent agent against pneumococci with MICs 0.03-0.06 mg/L. 2 Analysis of clinical trial data reveals a low to average incidence of class ADRs with gemifloxacin, although skin rashes are more common in young women. [12] [13] [14] Complete safety data on gemifloxacin remain to be published. Table 1 summarizes the characteristics of the quinolone generations and the class ADRs associated with each generation.
It may seem that rather more quinolones have left the stage than remain; however, increasing knowledge of structure-ADR relationships will ensure that this situation will not repeat itself. Remarkably, although amongst the first of the second-generation agents, ciprofloxacin remains amongst the safest of all antibiotics with remarkably few reports of serious reactions over a period of 15 years of use and more than 340 million prescriptions. 5,15 Levofloxacin has also established a similar reputation, 16 although questions may remain concerning tendinopathy and, perhaps, QT prolongation and related cardiac arrhythmias. 2, 6, 17 
Current fluoroquinolone ADR rates in context
It has become usual practice to label ADRs as either class or individual idiosyncratic effects. Class effects of fluoroquinolones are usually minor, and comprise gastrointestinal disorders, and CNS and skin disturbances. 5 As shown in Table 2 , they vary somewhat in incidence between agents. Differences may be accounted for by the patient interrogation methods prevailing in the 1980s, e.g. for ciprofloxacin and ofloxacin (also partly for levofloxacin), and the far stricter evaluation methods of the late 1990s, applying to moxifloxacin and gatifloxacin. There may also be geographical differences, usually reflecting patient stoicism. For example, the overall Phase III incidence of levofloxacin reactions in Japanese patients was 3.3%, 18 whereas the figure in Americans was up to 9.9% 16 rising to 18-20% in patients with respiratory infections. 19, 20 In comparative trials, Caucasians and Hispanics demonstrated higher rates of ADRs than African-Americans or Asians for both moxifloxacin and comparators. 21 Care must therefore be taken in comparing figures for different series and races.
However, variation in severity does occur within the scope of class effects and some specific problems attend certain 
2B
Balanced broad spectrum of activity; increased potency against pneumococci (MIC 0.25-0.5 mg/L); less potent against P. aeruginosa; class ADRs plus unexpected ADRs with individual agents (haemolytic-uraemic syndrome, QTc a prolongation, photoxicity); variable cytochrome P450 interaction with theophyllines 3A Enhanced activity against Gram-positive pathogens (pneumococci MIC 0.12-0.25 mg/L); class ADR profile; no cytochrome P450 interaction; specific ADRs with trovafloxacin, e.g. higher incidence of CNS effects, hepatic, allergic reactions and pancreatitis; specific effects with clinafloxacin, including hypoglycaemia and increased incidence of severity of phototoxicity
3B
Markedly enhanced activity against Gram-positive bacteria (pneumococci MIC 0.012 mg/L); retained activity against ciprofloxacin-resistant pneumococci; highly active against atypical respiratory tract infection pathogens; retained activity against Gram-negative pathogens; favourable ADR profile: low CNS ADR rate, no phototoxicity drugs, for example, dizziness with trovafloxacin 22 and taste perversion and nausea with grepafloxacin. 23 Some reactions may be more common in women, for example dizziness. 5,21 ADR-related discontinuation rates (usually of the order of 3-4%) can prove a more reliable means of comparison (Table  3 ). They will be seen to be somewhat higher for the agents recently withdrawn (and are unrelated to either trovafloxacin hepatitis or grepafloxacin-associated arrhythmias). Data for individual compounds vary widely, and differences between the types of comparator used should be taken into account. There will be significant differences between, for example, clarithomycin-and co-amoxiclav-treated patients. The results from Phase III clinical trials of moxifloxacin, compared with those of the standard comparators (clarithromycin and amoxicillin) are shown in Table 4 . 21 There are certain major class effects that vary in incidence and severity amongst the quinolones, often in association with known structural configurations. 5,24 These include the most recently recognized cardiac effects, phototoxicity, now almost completely designed out of modern compounds but latterly affecting clinafloxacin, CNS disturbance and tendinitis. The specific, individual quinolone-related serious organ-system related ADRs described with temafloxacin, tosufloxacin and trovafloxacin are almost certainly not general class effects.
Major class effects

Cardiac effects
The withdrawal of grepafloxacin on toxicological grounds, in association with sudden cardiac deaths and cases of torsade de pointes, focuses on a previously recognized but perhaps under-evaluated phenomenon first described with sparfloxacin: QT interval prolongation. 6,25 Prolongation of the rate-corrected QT interval (QTc) may be congenital or acquired either by disease process or drug exposure, and extreme prolongation may precipitate torsade de pointes (or other ventricular arrhythmias) clinically presenting with either syncope or sudden death. 26,27 Drugs so associated have included cisapride, anti-arrhythmics, terfenadine, fluoxetine and macrolides. However, quinolones were not highlighted as potential causes in reviews published as recently as 1999. 26, 27 Indeed, only single numbers of reports of quinolone-related torsade de pointes or ventricular tachycardia with sparfloxacin, 25,28,29 levofloxacin 30,31 and, more recently, grepa- All class members prolong the QT interval in rabbit and dog models. 5,6,23 However, there are significant differences in arrhythmogenic doses, for example, between grepafloxacin (10-30 mg/kg) and ciprofloxacin (300 mg/kg or more). 23 A class effect on the QTc is clearly present but, despite enormous exposure of at-risk populations to quinolones, these antibacterials have not generally been recognized as causes of the long QT syndrome, 26,27 associated ventricular tachy-arrhythmias or related fatalities. 6 Data on macrolides, which cause greater QTc prolongation than quinolones, also suggest that clinical effects are rare. 34 For example, a yearlong, retrospective, university-based study found QTc prolongation to be common and QT dispersion to double during intravenous erythromycin therapy. 35 However, although 39% of patients had moderate to severe hepatic dysfunction and pre-existing hypertensive and ischaemic heart disease, only one patient (0.4%) of those with prolonged QTc developed torsade de pointes.
The risk of arrhythmias rises with increased QT prolongation, 26 but critical values have not been established. However, risk factors may be cumulative, especially in combination with other drugs that cause QTc prolongation. 34 For later agents, no examples of adverse drug-related cardiac effects were noted in the clinical trials of either levofloxacin or gatifloxacin, 10,16 although post-marketing studies of both agents have revealed small numbers of cases of torsade de pointes. A case of polymorphic ventricular tachycardia associated with levofloxacin therapy has also been reported. 31 Both levofloxacin and gatifloxacin cause average QTc prolongation of 3-4 ms, although there is a wide variation in range. For moxifloxacin, QTc prolongation averaging approximately 4-6 ms (±26 ms) was observed during treatment in 9.5% of patients (9.2% for comparator agents), 6.5% of whom had a prolonged interval prior to quinolone exposure. 5, 6 QTc interval prolongation to >500 ms was observed in 0.13% of moxifloxacin-treated patients but there were no associated arrhythmias or pre-arrhythmic events in the entire clinical trial series. 21 Post-marketing surveillance, against a background of >10.5 million moxifloxacin-treated patients, revealed three confirmed cases of torsades de pointes, associated with multiple underlying factors predisposing to this arrhythmia, including female gender, advanced age, electrolyte disturbance, pre-existing cardiac disease and other drugs known to prolong QTc (data on file, Bayer AG). The incidence is similar to the background rate. 36 Although the risk of arrhythmia is extremely small, less than one per million treated cases for contemporary fluoroquinolones, 33,37 it is appropriate to recognize patients already at increased risk, e.g. elderly females with electrolyte disturbance or significant cardiac disease, those with a history of arrhythmia and/or who are receiving anti-arrhythmic or other agents known significantly to prolong the QT interval, e.g. antihistamines and cisapride. In such patients, quinolones should be used with caution. 6 
Major phototoxicity
It is recognized that multiply-fluorinated and 8-halogenated fluoroquinolones, notably 8-chloro-derivatives, such as Bay y 3118, clinafloxacin and sitafloxacin, are potentially severely phototoxic. 24 This has been confirmed by clinical experience and most such compounds have either not been registered or have been withdrawn. In contrast, 8-methoxy derivatives are unlikely to cause phototoxicity 38, 39 and clinical trials confirm this. 40, 41 For moxifloxacin, three of 5189 patients (<0.06%) in the trial series developed mild solar erythema possibly related to therapy. 21 
CNS disturbance
A number of quinolones have proved to have higher than average frequencies of CNS-related ADRs. In the past, problems have occurred with ofloxacin (sleep disturbance, confusion and, less commonly, psychiatric upset and convulsions) and lomefloxacin (significantly more frequent convulsions in patients without predisposing factors). 42 The most recent was trovafloxacin, primarily causing dose-related dizziness in up to 11% of patients. 43 Overall, in terms of spontaneous postmarketing reports in the USA, trovafloxacin caused considerably more CNS disturbances than levofloxacin, 26/100 000 compared with 4/100 000 treated patients. 43 Amongst newer agents, CNS disturbances are relatively uncommon. In Phase II/III trials, moxifloxacin (400 mg dose) was associated with an overall 7% incidence of CNS ADRs (comparators 5%) and, specifically, a 3% incidence of both dizziness and headache equivalent to comparator agents. 21 Headache was slightly more common with gatifloxacin (4%). 10 No other unusual effects were noted with either antibiotic. Ciprofloxacin caused CNS disorders in 1.6% of patients in Phase III evaluation, and dizziness in less than 0.5%. 44 
Tendinitis
Originally most commonly reported in association with pefloxacin, 45, 46 tendinitis, usually affecting the Achilles tendon, is a rare class effect. Reports to the US FDA MedWatch Spontaneous Adverse Events reporting system suggest frequencies of tendon disorder to lie between 0.05 (ciprofloxacin) and 0.6 (levofloxacin) per 100 000 treatments. 17 A case-controlled study has indicated fluoroquinolone use to carry an excess risk of 3.2 cases of Achilles tendon involvement per 1000 patient treatment years. 47 Tendinitis may be bilateral and can lead to rupture. Symptoms may persist for months and are significantly more common in the elderly, those receiving corticosteroid therapy and in terminal renal failure patients either on dialysis or with transplants. 46 MRI scanning is helpful in diagnosis; treatment is symptomatic.
Specific associated syndromes: the 1-(2,4)-difluorophenyl quinolones
The first evidence of serious unpredictable organ/system related toxicity of fluoroquinolones was the temafloxacin syndrome. 3 The 95 cases described in the US FDA report were characterized by onset of fever, rigors and jaundice a week into therapy, with associated haemolysis (mean drop 4 g/dL) and new onset renal insufficiency (57% of patients). Half of all cases were associated with hepatitis and an immunecomplex mediated, hypersensitivity reaction was thought to be the basis of the syndrome. In Japan, a warning letter has been issued by the registration authorities indicating renal dysfunction, skin hypersensitivity reactions and blood dyscrasias in association with tosufloxacin. Within the last 5 years, trovafloxacin has been restricted (USA) or suspended (Europe) due to severe hepatotoxicity, involving necrosis, failure and, in a very small minority of cases, both transplants and deaths. In cases where liver histology was available, centrilobular necrosis in association with eosinophilic infiltration was found. 5,7 The incidence was 0.0056% in a total of some 3 million treatment episodes. 5 This was sufficient to precipitate draconian regulatory action, although the figure was not dissimilar to that reported with co-amoxiclav, 48 which remains available.
All of these compounds, which produce severe immunologically mediated ADRs, have a single factor in common: the 1-(2,4)-difluorophenyl substituent. No other quinolones or naphthyridones have this feature, usually being characterized by a 1-cyclopropyl or 1,8-cyclo side-chain. None have produced similar reactions, although, as with many antibiotics, 49, 50 minor transaminase elevations (to three-to fivefold upper limit of normal in up to 5% of cases) may occur during therapy. For moxifloxacin, the incidence of such transaminase elevations was 3% and all abnormalities settled spontaneously without complication (data on file, Bayer AG). In comparison, elevated transaminases were observed in 1.4% of cases in Phase III clinical trials of ciprofloxacin. 44 
Conclusions
The fluoroquinolone group has made a major contribution to the care of infected patients for over 15 years. 8 Recent problems with idiosyncratic, unexpected and serious adverse reactions have affected very small numbers of patients and, whilst leading to the loss of the individual agents concerned, should not raise concerns about the class as a whole without scientific foundation. This appears to be lacking for traditional secondgeneration agents, such as ciprofloxacin, and post-marketing surveillance is currently confirming the safety of later derivatives, such as levofloxacin and the more potent 8-methoxy derivatives, moxifloxacin and gatifloxacin. With the exception of three confirmed cases of torsades de pointes, 17 all characterized by additional predisposing factors, no unpredictable events have been observed in >10.5 million patients treated with moxifloxacin.
The prime target for these new fluoroquinolones is pneumococcal respiratory infections, notably community-acquired pneumonia, in which the 8-methoxy quinolones are highly effective. 1 However, emergent resistance to second-generation fluoroquinolones (ciprofloxacin and levofloxacin) raises concerns that the whole group may be overcome before clinical use is established. 51 Clinical failures in association with the development of (levofloxacin) resistance are now being reported. [52] [53] [54] Nevertheless, the 8-methoxy quinolones, which are highly potent in vitro 55 and act against both the gyrA and parC targets, 56 retain activity against first step ciprofloxacinand levofloxacin-resistant mutants. 57, 58 After treatment of almost 20 million patients with these newer agents, their window of opportunity appears unlikely to be cut short by untimely reports of significant adverse reactions. 
